Veeva Systems reports fiscal Q1 2026 results on June 17 with analysts sharply divided on valuation and a stock that has lost a quarter of its value this year.
The most striking feature of the current setup is options positioning that has turned notably more bullish than usual — a contrast to the stock's recent weakness. The put/call ratio has dropped to 0.49, nearly 1.8 standard deviations below its 20-day average of 0.57. That's one of the most call-heavy readings of the past year, approaching but still above the 52-week low of 0.31. Investors are reaching for upside exposure rather than protection, even as the stock fell 7.6% on the week to close near $159.54. The lending market gives no reason for alarm: borrow availability remains extraordinarily loose at over 1,000% — roughly 13 shares available for every one currently borrowed — and cost to borrow has eased to around 0.41%, down roughly 17% over the past month.
Short interest is worth noting separately. At 5.3% of the free float, it is meaningful enough to matter, but the direction is the real story. Bears have been covering aggressively — shorts fell roughly 23% in a single week, dropping from around 11.3 million shares in early June to under 8.7 million. That's a sharp retreat from a position that had itself been built up fast: short interest rose 36% over the prior month before the recent unwind. The ORTEX short score has tumbled alongside it, sliding from around 47 a week ago to 42 now. Short sellers appear to be stepping back ahead of the print rather than pressing their case.
The analyst community is less united. After the most recent quarterly release on June 3 — which saw the stock fall 2.4% on the day and another 10.5% over the following five days — most major firms cut their targets on June 4. Goldman Sachs lowered its target to $165 while keeping a Sell rating, the most bearish call on the Street. Evercore ISI trimmed its target by more than 20% to $185. Citigroup bucked the trend, raising its target to $190 even while staying at Neutral. The range of price targets across the Street runs from $165 to $275, an unusually wide spread that reflects genuine disagreement about Veeva's growth trajectory. Bulls point to consistent revenue expansion, a diversified product portfolio in life sciences cloud, and the potential for accelerating demand from biopharma. Bears flag growth deceleration, competitive pressure, and a valuation that — with EV/EBITDA near 11 and a P/E around 17 — still looks rich relative to a more modest growth rate than Veeva once commanded. Peers have been mixed: TDOC gained 4.1% on the week while PHR fell 5%, offering no clean read from the sector.
The June 17 print will test whether the dramatic short-covering and the unusual call-heavy options skew reflect genuine conviction that growth concerns are already priced in — or simply pre-earnings repositioning ahead of another difficult quarter.
See the live data behind this article on ORTEX.
Open VEEV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
